Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects

An Open-label, Randomized, Fasting, Single-dose, Oral Administration, 2-sequence, 4-period, Replicate Crossover Study to Evaluate Bioequivalence Between YHP2508C and YHR2603 in Healthy Subjects

An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508C and YHR2603 in healthy subjects

44 healthy subjects will be randomized to one of 2 groups in the same ratio.

Subjects in group 1 will be administered "YHR2603" and "YHP2508C" by crossover design on periods 1 to 4.

Subjects in group 2 will be administered "YHP2508C" and " YHR2603" by crossover design on periods 1 to 4.

Inclusion Criteria:

• BMI 18-30 kg/m2
• Those without clinically significant congenital or chronic diseases

Exclusion Criteria:

• Those who have participated in a bioequivalence study or other clinical trials and have been administered investigational products within 6 months prior to the first administration.
• Those who are judged ineligible to participate in the trial by the principal investigator.
• Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.